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Introduction
Cardiovascular (CV) disease continues to be a significant cause of morbidity and mortalitycoronary disease and cerebrovascular disease are the second and third leading causes of death, respectively, in Canada. 1 In 2007, a set of dyslipidemia guidelines tailored to pharmacists based on the 2006 Canadian Cardiovascular Society (CCS) recommendations was published in the Canadian Pharmacists Journal. 2 Since then, pharmacists in many provinces have expanded their scope of practice, including in some cases the ability to independently prescribe or modify existing therapies and order laboratory tests. There is growing evidence that pharmacist intervention in the management of dyslipidemia leads to improvements in lipid management. 3 Moreover, expanding evidence in the realm of dyslipidemia, including trials in previously understudied populations (chronic kidney disease), innovations in CV risk communication (Cardiovascular Age) and increased awareness of the adverse effect profile of statins led to the publication of the 2012 update of the CCS guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. 4 In this article, we provide an update based on the current CCS guidelines, with practical tips for pharmacists.
Screening
Pharmacists in all practice settings can play a key role in screening individuals for dyslipidemia and overall CV risk. The CCS screening recommendations, which can serve as a template for a focused patient history and clinical assessment, are summarized in Table 1 . In addition to undergoing a routine fasting lipid panel, individuals should also be screened for hypertension, diabetes and chronic kidney disease (CKD) using appropriate laboratory tests.
Cardiovascular risk assessment
a) Pharmacists should actively engage with patients in discussion of CV risk. b) The following patients are considered to be at high CV risk; therefore, the use of a CV risk calculator (intended for primary prevention) is neither necessary nor appropriate:
• Clinical evidence of atherosclerosis, as detailed in • Accuracy: No tool exists that predicts who will experience a CV event with 100% certainty. With that in mind, the Framingham Risk Score (FRS) provides a reasonable estimate of risk and has stood "the test of time, " with its predictive power only modestly improving when adding newer, more expensive tests (see "Secondary testing" below). • Age: In the Framingham Heart Study, increasing age was one of the strongest risk factors for a CV event and contributes heavily to a patient's FRS. Thus, patients who maintain the same level of control of their modifiable CV risk factors will still have an increasing FRS over time. Additionally, the FRS becomes less accurate at the higher extremes of age because of the natural increasing comorbidity burden, particularly cancer, with age. • Family history: The CCS guidelines recommend doubling of calculated Framingham 10-year CV percent risk for patients (age 30-59) who have a family history of premature CV disease, which is referred to as the modified FRS. The modified FRS awaits formal validation. In otherwise low-risk patients, the modified FRS may overestimate risk and lead to overtreatment. 13 • Patients receiving treatment: The Framingham calculator was not intended for use in patients already receiving pharmacotherapy for CV risk management. For example, the Framingham calculator does not take into account the use of ASA, or the inferior CV reduction of b-blockers, despite similar blood pressure reduction compared with other antihypertensives. 14 • Risk categories: The CCS acknowledges that the 3 risk categories used in the guidelines are arbitrary but useful yardsticks that should be supplemented by clinical judgment and patient values whenever possible. • Secondary testing: Some of the most widely used secondary testing methods are the ankle-brachial index (ABI), highsensitivity C-reactive protein (hs-CRP) and coronary artery calcium (CAC). ○ ABI: Measures the ratio of systolic blood pressure between the legs and arms. A lower ratio (especially <0.90) indicates decreased perfusion pressure to the lower extremities, which strongly suggests peripheral artery disease (PAD). Patients with PAD have similar CV risk as those with existing CAD and should be targeted with aggressive CV reduction. 15 Evidence of efficacy and safety:
PRaCtiCe GUideLiNeS
• Available on the Canadian market since 2003, there is no published evidence to date that confirms that ezetimibe's effect on LDL-C reduction decreases CV events. The SHARP study did demonstrate that the combination of simvastatin and ezetimibe decreased CVD events in subjects with chronic kidney disease compared with placebo; however, no statin-only arm was tested, and the relative contribution of ezetimibe to the CVD reduction cannot be determined. 24 Overall, ezetimibe is well tolerated, and an ongoing large RCT is slated to shed some light on the long-term effect of ezetimibe on CV and non-CV clinical outcomes.
Other uses:
• Familial hypercholesterolemia
Fibrates
Evidence of efficacy and safety:
• In patients not receiving a statin, fibrates have shown a small reduction in nonfatal CV events. 25 Conversely, in the ACCORD trial of type 2 diabetic patients already receiving a statin, fenofibrate did not produce a statistically significant reduction in CV events. 26 Therefore, there appears to be a small role for fibrates in patients unable to take a statin but not as adjunctive therapy to statins. As with statins, fibrates can cause muscle-related symptoms and rhabdomyolysis.
• Treatment of hypertriglyceridemia to prevent pancreatitis Niacin Evidence of efficacy and safety:
• The Coronary Drug Project, a randomized, placebo-controlled secondary prevention trial conducted between 1966 and 1975, demonstrated a significant reduction in CVD events in patients treated with niacin compared with placebo. 27, 28 More recently, 2 large RCTs failed to identify any CV benefit of niacin when added to statin therapy. 29, 30 Additionally, intolerance to niacin is common, primarily due to flushing, itching and gastrointestinal upset. Additional adverse effects related to niacin include diabetes, liver enzyme elevations and myopathy. Thus, niacin's potential place in therapy is in a small subset of patients who have contraindications to statins but can tolerate niacin.
Omega-3 fatty acids Evidence of efficacy and safety:
• Although observational studies and early RCTs suggested a beneficial effect of omega-3 fatty acid intake on CV events, modern, higher quality meta-analyses and RCTs have not demonstrated any beneficial CV effects of omega-3 fatty acid supplementation. 31, 32 It is still reasonable to recommend omega-3-rich foods such as fish, but nondietary omega-3 fatty acid supplementation is no longer recommended.
• Treatment of hypertriglyceridemia to prevent pancreatitis RCT, randomized controlled trials; CV, cardiovascular; LDL-C, low-density lipoprotein cholesterol; CVD, cardiovascular disease. 
Lipid targets
The CCS guidelines recommend the following lipid targets: a) For high-and intermediate-risk individuals:
• LDL-C level ≤2.0 mmol/L or a ≥50% reduction from baseline • Alternate treatment targets include apoB ≤0.8 g/L or non-HDL-C ≤2.6 mmol/L. b) For low-risk individuals, a reduction in LDL-C ≥50% from baseline is recommended.
Lifestyle changes
a) Healthy eating habits should be encouraged in all individuals, particularly those at higher risk of CV disease, including the following recommendations:
• Consume sufficient calories to maintain a healthy body weight • Eat a diet rich in vegetables, fruit, wholegrain cereals and polyunsaturated and monounsaturated oils • Avoid trans fats and limit saturated and total fats to <7% and <30% of daily total caloric intake, respectively are anecdotal reports of statins causing cognitive impairment, a systematic review of 57 studies, including RCTs and real-world cohorts, showed that statins do not increase the incidence of dementia or worsen performance on cognitive function tests. 8 e) Myalgias: Because statins have the strongest and most consistent evidence for CV reduction of any lipid-lowering therapy, the goal should be to find a tolerable statin-based regimen before moving down to alternate lipid-lowering agents that either lack clinical outcome evidence or have evidence of no effect. For statin-related myalgia, evidence supports strategies of switching to a different statin, implementation of alternate-day statin dosing regimens, as well as N-of-1 trials-in accordance with the patient-to find a tolerable statin regimen. 7, 9 In contrast, evidence for the efficacy of concomitant use of coenzyme Q10, vitamin D or any other supplement, vitamin or mineral is of low quality and inconsistent; therefore, these agents should not be recommended for this indication. f) Diabetes: Statins should not be withheld because of the small increase in blood glucose.
• In one meta-analysis, for every 255 individuals initiating a statin, 1 extra person developed diabetes over 4 years. 10 Conversely, statins prevented 5.4 CV events for every additional case of diabetes. This effect seems to be dose-dependent, with an additional case of diabetes over 5 years for every 125 patients initiating a higher versus lower dose statin. 11 Likewise, the higher statin dose prevented 3.2 CV events for each new case of diabetes caused. • To quantify this in another way, a cohort study found that statin use was associated PRaCtiCe GUideLiNeS with a fasting blood glucose that was approximately 0.1 mmol/L higher than nonuse at 2 years. A small 2-month RCT found an increase in hemoglobin A1c of approximately 0.3% with atorvastatin 10-80 mg versus placebo. In patients already at risk of diabetes (e.g., metabolic syndrome, body mass index ≥30 or prediabetes), this small increase in blood glucose measures may be sufficient to push an individual patient above the diagnostic threshold for diabetes. Ultimately, these patients are also at higher CV risk and thus more likely to benefit from statin therapy. Fortunately, such a small increase in blood glucose is unlikely to lead to increased risk of dia- 
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BOX 1
The Canadian-American controversy: "Treat-to-target" vs "Fire-and-forget"?
Over the years, 2 predominant strategies have been developed to manage use of lipid-lowering therapies: Treat-to-target and fire-and-forget.
The treat-to-target approach, endorsed by the 2012 CCS guidelines, involves intensifying lifestyle and pharmacologic treatment in order to achieve specific lipid levels. Advocates for treating to target lipid levels point to the pathophysiologic role of LDL-C in atherosclerosis formation and observational association between lower achieved lipid levels and reduced risk of CV events as evidence for this strategy.
The fire-and-forget approach, endorsed by the 2013 ACC/AHA dyslipidemia guidelines, 19 fundamentally involves measuring lipid levels only for the sake of initial CV risk prediction. Once therapy is initiated, routine lipid panels are not repeated and no particular absolute or relative lipid targets are sought. Drug therapy involves the initiation of a "lipid-lowering drug" (usually a statin) at a fixed dose that has demonstrated benefit in RCTs. A higher dose (such as atorvastatin 80 mg once daily) may be attempted, as RCTs have shown a marginal further reduction in CV events up to this higher dose range, with concomitant increase in typical statin adverse effects (see "Statin monitoring and toxicity" section). 20 Fire-and-forget advocates generally avoid using nonstatin lipid-lowering agents, as most have generally failed to reduce CV events in RCTs (see Table 4 ).
For a detailed review of the similarities and differences between international guidelines, the interested reader is referred to additional references. 21, 22 However, for the purposes of clinical management of patients, practitioners should adhere to the recommendations of the Canadian Cardiovascular Society. This article provides the details of those guidelines, which will continue to updated as new information becomes available.
CCS, Canadian Cardiovascular Society; LDL-C, low-density lipoprotein cholesterol; ACC/AHA, American College of Cardiology/American Heart Association; RCT, randomized controlled trial.
